Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.52 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382709 | 0.96 | PARP1 (0.65) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL14406 | 0.96 | PARP1 (0.65) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL142937 | 0.96 | PARP1 (0.65) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL6907818 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| Ammonia Solution, Strong SCHEMBL1667008 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL6915713 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| Bromide SCHEMBL6113526 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL6916592 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| Iodide SCHEMBL6113184 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL1151724 | 0.93 | PARP1 (0.63) | PARP1POLBSMN1; SMN2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937614-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | Arcadia Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| WO-2007047776-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | PARP1 3139/4885POLB 1159/4885SMN1; SMN2 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.